NovoPedics

NovoPedics is a private, pre-revenue biotechnology company pioneering a regenerative medicine solution for meniscus repair. Its core technology is MeniscoFix™, a bioresorbable, fiber-reinforced scaffold designed to replace damaged meniscal tissue and be naturally resorbed and replaced by new, native-like tissue. The company has achieved significant non-dilutive funding through NIH SBIR grants and Department of Defense awards, and its device has received FDA Breakthrough Device Designation, indicating a high unmet medical need. NovoPedics is currently in the pre-clinical and development stage, advancing toward clinical trials for a large orthopedic market with limited treatment options.

Bioresorbable, fiber-reinforced polymer scaffolds designed to mimic native tissue architecture and guide in vivo regeneration of load-bearing soft tissues.

The market for total meniscus replacement is currently served only by cadaver allografts, which have limitations. NovoPedics competes with companies developing partial meniscal scaffolds (e.g., collagen-based implants) and allograft providers, but its fiber-reinforced, bioresorbable design for total replacement is a differentiated approach. Larger orthopedic giants pose a potential competitive threat if they enter the space.